drugset / Trial / NCT05442437

Clinical Study of hUC-MSCs Treating Decompensated Liver Cirrhosis With HBV

NCT05442437

Phase 0 Completed 24 enrolled Zhongnan Hospital
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study was to observe the safety ,tolerability ,Efficacy dose of human umbilical cord mesenchymal stem cells in patients of decompensated liver cirrhosis with HBV.

Timeline

Start
2019-09-08
Primary completion
2022-07-01
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject human umbilical cord mesenchymal stem cells Cell therapy 2.5e+07 cells Intravenous
Subject human umbilical cord mesenchymal stem cells Cell therapy 5e+07 cells Intravenous
Subject human umbilical cord mesenchymal stem cells Cell therapy 1e+08 cells Intravenous